Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05900206 | Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer(ARIADNE) | recruiting | Phase 2 | 370 | Karolinska University HospitalOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT07134153 | Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain Metastases(INOVATE) | recruiting | Phase 1 / Phase 2 | 139 | Fudan UniversityOTHER | 1 | Aug 21, 2025 |
| clinicaltrials |
| NCT05744687 | Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer | recruiting | Phase 2 / Phase 3 | 374 | Shanghai Pharmaceuticals Holding Co., LtdINDUSTRY | 1 | Aug 17, 2025 | clinicaltrials |
| NCT06611813 | Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01) | recruiting | Phase 2 | 30 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT06874933 | Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03) | recruiting | Phase 2 | 35 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT03740893 | PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer(PHOENIX) | recruiting | Phase 2 | 119 | Institute of Cancer Research, United KingdomOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT07113613 | Prospective Study on Exemption of Tumor Bed Boost Radiotherapy for pCR Patients After Breast Conserving Surgery With Neoadjuvant Therapy | recruiting | Phase 2 | 150 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT07108309 | BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer(AREAL) | recruiting | Phase 2 | 124 | BiocadINDUSTRY | 2 | Aug 7, 2025 | clinicaltrials |
| NCT07104266 | Triple Negative Breast Cancer and Celecoxib. Pilot Study | recruiting | Phase 2 | 30 | Université de SherbrookeOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT05035745 | Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START) | recruiting | Phase 1 / Phase 2 | 63 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05181033 | Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor | recruiting | Phase 2 | 120 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT05491083 | Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer(ComPACT) | recruiting | Phase 1 / Phase 2 | 51 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT07065435 | RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study | recruiting | Phase 2 | 74 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT06402435 | SBRT, Chemotherapy, and AK112 Neoadjuvant Therapy for Luminal-type Breast Cancer | recruiting | Phase 2 | 50 | Hubei Cancer HospitalOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT06500208 | Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC | recruiting | Phase 2 | 48 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT06665178 | Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer | recruiting | Phase 2 | 20 | British Columbia Cancer AgencyOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT06568692 | A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer | recruiting | Phase 2 | 90 | Processa PharmaceuticalsINDUSTRY | 1 | Jun 19, 2025 | clinicaltrials |
| NCT06150898 | Ketorolac and Pregabalin Effects on breaSt Cancer (KePreSt)(KePreSt) | recruiting | Phase 2 | 112 | Jules Bordet InstituteOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT07014410 | Pyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-positive and HER2-positive Advanced Breast Cancer | recruiting | Phase 2 | 63 | Zhejiang Cancer HospitalOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT06678048 | Arsenous Acid for Refractory Triple-Negative Breast Cancer | recruiting | Phase 2 | 12 | Sun Yat-sen UniversityOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT06993714 | 3D-printed Biodegradable Breast Implants for Breast Restoration | recruiting | Phase 2 | 120 | Xijing HospitalOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT06677879 | A Prospective Cohort Study of Proton and Photon Therapy for Left-sided Breast Cancer. | recruiting | Phase 2 | 780 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT06049355 | EMBRACE: Exercising Together | recruiting | Phase 2 | 400 | OHSU Knight Cancer InstituteOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT06992336 | Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy | recruiting | Phase 2 | 411 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT06367088 | Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer | recruiting | Phase 2 | 27 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT04947189 | Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer(4CAST) | recruiting | Phase 1 / Phase 2 | 65 | St Vincent's Hospital, SydneyOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06165419 | Definitive Radiation for High-Risk Spine Metastases | recruiting | Phase 2 | 26 | Stony Brook UniversityOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT06958627 | The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study(any) | recruiting | Phase 2 / Phase 3 | 964 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT04503265 | A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 122 | AtlasMedx, IncorporatedINDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT06207734 | Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer | recruiting | Phase 2 | 120 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT06225284 | Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients(ESCALATE) | recruiting | Phase 2 | 124 | National Taiwan University HospitalOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT05535413 | UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases | recruiting | Phase 1 / Phase 2 | 30 | Hunan Cancer HospitalOTHER | 1 | Apr 25, 2025 | clinicaltrials |
| NCT05288777 | Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer(Breast53) | recruiting | Phase 2 / Phase 3 | 45 | University of VirginiaOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT04892693 | Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency | recruiting | Phase 2 | 70 | Seoul National University HospitalOTHER | 1 | Apr 17, 2025 | clinicaltrials |
| NCT05536128 | Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor(Post-CDK) | recruiting | Phase 2 | 64 | Seoul National University HospitalOTHER | 1 | Apr 17, 2025 | clinicaltrials |
| NCT05013255 | Pioglitazone Therapy Targeting Fatigue in Breast Cancer | recruiting | Phase 2 | 30 | West Virginia UniversityOTHER | 1 | Apr 8, 2025 | clinicaltrials |
| NCT04680442 | Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction(SCHOLAR-2) | recruiting | Phase 2 | 130 | Population Health Research InstituteOTHER | 3 | Apr 6, 2025 | clinicaltrials |
| NCT06811870 | A Phase II Single-Arm Clinical Study to Explore the Efficacy and Safety of Hyperbaric Oxygen in the Neoadjuvant Treatment of Breast Cancer Patients | recruiting | Phase 1 / Phase 2 | 161 | Guangdong Provincial People's HospitalOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT05955170 | Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer(TUC-TOC) | recruiting | Phase 2 | 66 | Institut CurieOTHER | 1 | Mar 27, 2025 | clinicaltrials |
| NCT05332561 | Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE) | recruiting | Phase 2 | 240 | German Cancer Research CenterOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT05485766 | Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer | recruiting | Phase 2 | 23 | Okayama UniversityOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT06880029 | Circadian Rhythm Impact on TNBC Response to Neoadjuvant Immunotherapy(CIRCADIAN) | recruiting | Phase 1 / Phase 2 | 20 | Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.OTHER_GOV | 1 | Mar 19, 2025 | clinicaltrials |
| NCT05816655 | Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer | recruiting | Phase 2 | 202 | Korea University Guro HospitalOTHER | 1 | Mar 18, 2025 | clinicaltrials |
| NCT05918328 | Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC | recruiting | Phase 2 | 610 | Henan Cancer HospitalOTHER_GOV | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06193525 | FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test(FUTURE) | recruiting | Phase 2 | 66 | Erasmus Medical CenterOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT06851299 | The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast Cancer. | recruiting | Phase 2 | 60 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT05020860 | Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer(RESPONSE) | recruiting | Phase 2 | 185 | Baylor Breast Care CenterOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT04990921 | Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer | recruiting | Phase 2 | 15 | University of LouisvilleOTHER | 1 | Feb 20, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Sep 2, 2025source: clinicaltrials